Latest Releases

20 October 2011  Syntaxin and Ipsen enter into a strategic agreement to develop novel botulinum-toxin therapeutics

Ipsen (Euronext: IPN, ADR: IPSEY) and Syntaxin, a biotechnology company specialising in innovative biopharmaceutical therapies targeting cell secretion pathways, announced today a global strategic col...

View

14 June 2011  Syntaxin and University School of Medicine, Geneva were awarded the Presidential Poster Prize at ENDO 2011, the Endocrine Society’s 13th Annual meeting held in Boston Mass 4-7th June 2011

...

View

11 May 2011  Syntaxin enters manufacturing agreement with SynCo Bio Partners B.V

Oxford, UK, 11th May 2011: Syntaxin, a biotechnology company specialising in innovative biopharmaceutical therapies for cell secretion control, is pleased to announce a manufacturing agreement with Sy...

View

02 March 2011  Syntaxin announces its partner Allergan enters Phase II trials with Re‐Targeted Endopeptidase Drug

Oxford, UK, 2nd March 2011: Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, today announces its partner Allergan Inc has initiated two Phase II trials...

View

07 January 2011  Russell G. Greig Appointed as Chairman

Oxford, UK, 6th January 2011: Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, today announced Dr Russell G. Greig, Ph. D., has been appointed as Chairm...

View

29 November 2010  Melanie Lee joins BTG plc Board as Non-Executive Director

BTG plc (LSE:BGC), the specialty pharmaceuticals company, today announces the appointment of Dr Melanie Lee CBE as a non-executive director of the Board, effective from today....

View

11 November 2010  Syntaxin Raises £18 million in New Financing

Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, announces it has successfully raised £18 million in new funding....

View

01 February 2010  Syntaxin Announces Appointments of CEO, CBO and CDO

Syntaxin announced today the appointment of Melanie Lee, PhD, CBE, FMedSci, DSc as the company’s Chief Executive Officer, Nigel Clark, PhD as Chief Business Officer and Jon Court, PhD as Chief Develop...

View

30 September 2009  Syntaxin Appoints Executive Chairman

Syntaxin, a biopharmaceutical company developing novel biologic drugs that control cell secretion, today reports that Andrew Sandham has been appointed Executive Chairman. This follows the resignation...

View

28 July 2008  Syntaxin announces entry of pain drug candidate into phase 1 clinical evaluation

Syntaxin Ltd (“Syntaxin” or “the Company”), a biopharmaceutical company developing novel biologic drugs that control cell secretion, today reports that its partner, Allergan Inc, is to initiate clin...

View

17 March 2008  Syntaxin Appoints Eduard E Holdender to its BOD

Syntaxin Ltd (“Syntaxin” or “the Company”), a biopharmaceutical company developing novel biologic drugs that control cell secretion, today ann...

View

12 February 2008  Syntaxin Appoints CMO and Head of Cell Biology

Syntaxin Ltd (“Syntaxin” or “the Company”), a biopharmaceutical company developing novel biologic drugs that control cell secretion, today announces that it has appointed Richard Jones, MD as Chief ...

View

01 October 2007  Syntaxin Raises 16m to Advance Development of Novel Drug Pipeline

Syntaxin Ltd, a biopharmaceutical company developing novel biologic drugs that control cell secretion, today announces that it has raised $32 million in a Series B fundraising. The round was co-led ...

View

01 March 2007  Syntaxin Appoints Philip Boyd as CFO

Syntaxin, Ltd, a biopharmaceutical company focusing on the discovery and development of novel drugs to control cell secretion, today announced the appointment of Philip Boyd as Chief Financial Officer...

View

04 September 2006  Syntaxin Expands its Strategic Alliance with Allergan for Novel Therapeutic Compounds

Syntaxin Ltd (Syntaxin), a biopharmaceutical company focusing on designing and developing bacterial-based therapeutic proteins for the treatment of neurological, respiratory and metabolic diseases, ...

View

06 July 2006  :Syntaxin Wins Collaborative DTI Grant to Invest BioPharmaceutical Processing

Syntaxin Ltd (Syntaxin), a newly formed biopharmaceutical company focusing on the discovery and development of new medicines derived from bacterial toxins to treat chronic diseases, has been awarded...

View

14 November 2005  Syntaxin Launches in Spin Out of Medicines Discovery Programme from UK HPA

Syntaxin Ltd (Syntaxin), a newly formed biopharmaceutical company focussing on the discovery and development of new medicines for the treatment of neurological, respiratory and metabolic diseases, was...

View